pt dxd covid on 5/6; started paxlovid on 5/7 and completed 5 day course. he had improvement of sx but not resolution. home covid test neg x 2. and then on 5/23 home covid test + again due to persisting sxs; This spontaneous case was reported by a physician and describes the occurrence of COVID-19 (pt dxd covid on 5/6; started paxlovid on 5/7 and completed 5 day course. he had improvement of sx but not resolution. home covid test neg x 2. and then on 5/23 home covid test + again due to persisting sxs) in a 33-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product NIRMATRELVIR, RITONAVIR (PAXLOVID) for COVID-19 treatment.    Concurrent medical conditions included Allergy to animal (Allergy to Dog), Allergy to animal (Allergy to Cat), Drug allergy (Ibuprofen Allergy), Asthma, Ulcerative colitis, Eosinophilic esophagitis and Aortic regurgitation. Concomitant products included ESOMEPRAZOLE, FLUTICASONE PROPIONATE, SALMETEROL XINAFOATE (ADVAIR), FLUTICASONE PROPIONATE (FLOVENT) and MESALAMINE for an unknown indication.   On 07-May-2022, the patient started NIRMATRELVIR, RITONAVIR (PAXLOVID) (unknown route) at an unspecified dose. On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 23-May-2022,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced COVID-19 (pt dxd covid on 5/6; started paxlovid on 5/7 and completed 5 day course. he had improvement of sx but not resolution. home covid test neg x 2. and then on 5/23 home covid test + again due to persisting sxs). At the time of the report, COVID-19 (pt dxd covid on 5/6; started paxlovid on 5/7 and completed 5 day course. he had improvement of sx but not resolution. home covid test neg x 2. and then on 5/23 home covid test + again due to persisting sxs) was resolving. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 06-May-2022, SARS-CoV-2 test: positive (Positive) Positive. On 23-May-2022, SARS-CoV-2 test: positive (Positive) Positive. On an unknown date, SARS-CoV-2 test: negative (Negative) Negative and negative (Negative) Negative.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   The patient was on other medications/products within 2 weeks of starting COVID-19 treatment. Patient had improvement of symptoms but no resolution. On 23-May-2022 patient had covid test positive again due to persisting symptoms. Device Date : 23May2022 No treatment information was provided. Company comment: This spontaneous case concerns a 33-year-old, male patient with no relevant medical history, who experienced the unexpected, non-serious AESI of COVID-19. The exact date of administration of third dose of mRNA-1273 was not specified in respect to the onset of the event, hence latency could not be assessed. There was no information provided regarding the initial two doses. On May 6 and 23, 2022, SARS-CoV-2 test was done which revealed a positive result, on an unknown date it yielded a negative result. It has been reported that the patient underwent a 5-day treatment regimen of Paxlovid and have improvement of symptoms. Details of concomitant medications, medical history and clinical course were not provided. The benefit-risk relationship of mRNA-1273 is not affected by this report.; Sender's Comments: This spontaneous case concerns a 33-year-old, male patient with no relevant medical history, who experienced the unexpected, non-serious AESI of COVID-19. The exact date of administration of third dose of mRNA-1273 was not specified in respect to the onset of the event, hence latency could not be assessed. There was no information provided regarding the initial two doses. On May 6 and 23, 2022, SARS-CoV-2 test was done which revealed a positive result, on an unknown date it yielded a negative result. It has been reported that the patient underwent a 5-day treatment regimen of Paxlovid and have improvement of symptoms. Details of concomitant medications, medical history and clinical course were not provided. The benefit-risk relationship of mRNA-1273 is not affected by this report.